Achieving Long-Term Protection Post-MI

Slides:



Advertisements
Similar presentations
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Advertisements

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
_________________ Caitlin M. Gibson, PharmD, BCPS
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
DES Should be Used as the Default Stent in ACS!
Ischaemic Heart Disease Acute Coronary Syndrome
European and US Guidelines
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Preventing Thrombotic Complications in ACS: State of the Art
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
Atrial Fibrillation and PCI
Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.
Glenn N. Levine et al. JACC 2016;68:
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Gilles Montalescot, ACTION Study Group, Paris
Emerging Data on ACS Management From ACC
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
PAD Patients vs Post-ACS Patients:
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Glenn N. Levine et al. JACC 2016;68:
CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Introduction Antiplatelet Agents ADP Receptor Antagonists.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
Select Topics in Cardiovascular Medicine
Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum
Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.
Antithrombotics and PAD: A New Paradigm in Practice
New Perspectives in CAD and PAD: Weighing the Latest Evidence
What Has Been Tried and What Is True?
Tailoring Antiplatelet Therapy in PCI
Antiplatelet Therapy and Secondary Prevention
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Terms of Use. Terms of Use.
Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.
NOACS: Emerging data in ACS/IHD
CV Risk Doesn't End in the Cath Lab
AF and PCI in Practice.
Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
CV Risk Doesn't End in the Cath Lab
Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
Duration of Dual Antiplatelet Therapy
Factor Xa Inhibitors in PAD
What oral antiplatelet therapy would you choose?
Elevated Admission Plasma Glucose Following ACS
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum
Maintenance of Long-Term Clinical Benefit with
Primary safety endpoint
OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.
ESC Guideline on the Management of STEMI Recommendation for DAPT
Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.
Section C: Clinical trial update: Oral antiplatelet therapy
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Antithrombotic Therapy in AF Patients Undergoing PCI
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Translating Data From Trial to Practice
Presentation transcript:

Achieving Long-Term Protection Post-MI

Panelists

Program Goals

Case Study 1

Case Study 1 (cont)

Case Study 1 (cont)

Safe to Stop DAPT?

Risk Scores From PARIS

Elective Surgery Timing in STEMI Patient With DES

Risk of MACE Following Noncardiac Surgery in Patients Post-PCI

Leading Risk Factors for MACE Post-Noncardiac Surgery in PCI Patients

Platelet Reactivity and Clinical Outcomes at 1-Year Follow-Up: ADAPT-DES

DES vs BMS 5 Study Meta-Analysis

ZEUS Trial

LEADERS FREE

Length of DAPT: STEMI Treated With DES US Perspective

Post-STEMI Treated With DES: Duration of DAPT European Perspective

Case Study 2

Case Study 2 (cont)

Case Study 2 (cont)

Euro Heart Survey: In-Hospital Use of Interventional Strategies for ACS

PLATO Cumulative Incidence of Primary Composite of CV Death, MI, and Stroke in Patients Intended for Noninvasive Management

TRILOGY ACS

CHARISMA

Markers of Increased Risk in Our Patient

Ischemic Risk and Efficacy of Ticagrelor in Relation to Time From P2Y12 Inhibitor Withdrawal

Bleeding Risk Score Patients With ACS

THEMIS

MATCH Outcomes

Calculation of a DAPT Score

PPIs

Cardiovascular OutcoMes for People Using Anticoagulation StrategieS

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT)

GLOBAL LEADERS: A Clinical Study Comparing 2 Forms of Antiplatelet Therapy After Stent Implantation

Concluding Comments

Abbreviations

Abbreviations (cont)

Abbreviations (cont)